990 resultados para Field trials


Relevância:

20.00% 20.00%

Publicador:

Resumo:

no.4(1922)

Relevância:

20.00% 20.00%

Publicador:

Resumo:

v. 42 (1971)

Relevância:

20.00% 20.00%

Publicador:

Resumo:

v. 41 (1970)

Relevância:

20.00% 20.00%

Publicador:

Resumo:

v. 44 (1973)

Relevância:

20.00% 20.00%

Publicador:

Resumo:

v.2:no.1(1900)

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Observations reported in the present paper have shown that Biomphalaria glabrata is being gradually displaced by B. straminea in coastal areas of two counties on the state of Pernambuco, Brazil, confirming former observations made in the same region.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Paragonimus rudis was found in the lungs of a giant otter Lutra (pteronura) brasiliensis by Natterer in 1828, who dissected the animal in the former capital Mato Grosso (=Vila Bela), Brazil. The flukes were described by Diesing in 1850, and redescribed by Braun in 1901. Both descriptions do not allow to identify the species. Therefore, P. rudis must be regarded a "nomen nudum". Because its rediscovery is desirable with regard to historical reasons and nomenclatoric questions, a field study was performed in Mato Grosso in 1980. Of 354 freshwater crabs from 24 localities collected and examined for parasitic infections, about 25% were found to be infected with 7kinds of trematode larvae, which differed distincly from Paragonimus-metacercariae. The question, whether P. rudis or other lung fluke species do not seem to occur or cannot be found any longer in the area investigated by us, is discussed.

Relevância:

20.00% 20.00%

Publicador:

Resumo:

Scandals of selective reporting of clinical trial results by pharmaceutical firms have underlined the need for more transparency in clinical trials. We provide a theoretical framework which reproduces incentives for selective reporting and yields three key implications concerning regulation. First, a compulsory clinical trial registry complemented through a voluntary clinical trial results database can implement full transparency (the existence of all trials as well as their results is known). Second, full transparency comes at a price. It has a deterrence effect on the incentives to conduct clinical trials, as it reduces the firms'gains from trials. Third, in principle, a voluntary clinical trial results database without a compulsory registry is a superior regulatory tool; but we provide some qualified support for additional compulsory registries when medical decision-makers cannot anticipate correctly the drug companies' decisions whether to conduct trials. Keywords: pharmaceutical firms, strategic information transmission, clinical trials, registries, results databases, scientific knowledge JEL classification: D72, I18, L15